ASLAN Pharmaceuticals Pte Ltd

218 articles with ASLAN Pharmaceuticals Pte Ltd

• ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

  3/24/2023

  ASLAN Pharmaceuticals today announced financial results for the fourth quarter and full year ended December 31, 2022, and provided an update on recent corporate activities.

• ASLAN Pharmaceuticals to Participate in Fireside Chat at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference

  3/22/2023

  ASLAN Pharmaceuticals today announced Dr. Carl Firth, CEO, will be available for one-on-one meetings and participate in a fireside chat at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference being held on March 30, 2023.

• ASLAN Pharmaceuticals Announces Acceptance of Two Abstracts for Poster Presentation at the 1st International Societies for Investigative Dermatology Meeting

  3/14/2023

  ASLAN Pharmaceuticals today announced that two abstracts on eblasakimab have been accepted for poster presentation at the 1st International Societies for Investigative Dermatology Meeting, taking place from May 10 to 13, 2023, in Tokyo, Japan.

• ASLAN Pharmaceuticals Announces Plan to Implement ADS Ratio Change

  3/10/2023

  ASLAN Pharmaceuticals today announced that it plans to change the ratio of the American Depositary Shares (“ADSs”) to its ordinary shares, par value $0.01 per share, from one (1) ADS representing five (5) ordinary shares to one (1) ADS representing twenty-five (25) ordinary shares.

• ASLAN Pharmaceuticals to Host Virtual Research and Development Day on Novel DHODH Inhibitor Farudodstat for Alopecia Areata

  3/8/2023

  ASLAN Pharmaceuticals today announced that it will be hosting a virtual research and development day on Thursday, March 16, 2023, from 10:00 am – 11:30 am ET.

• ASLAN Pharmaceuticals Announces Completion of Recruitment in Phase 2b TREK-AD Study of Eblasakimab in Atopic Dermatitis Patients

  2/24/2023

  ASLAN Pharmaceuticals today announced that it has enrolled the final patient in TREK-AD, a Phase 2b dose-ranging clinic study of eblasakimab in adults with moderate-to-severe atopic dermatitis (AD).

• ASLAN Pharmaceuticals Announces $20M Private Placement Led by BVF Partners L.P. With the Potential to Receive Up to an Additional $80M

  2/24/2023

  ASLAN to receive $20 million in financing with the potential to receive up to an additional $80 million for an aggregate of $100 million to continue advancing the clinical development of eblasakimab and farudodstat.

• ASLAN Pharmaceuticals and Thermo Fisher Scientific Announce Partnership to Manufacture High Concentration Formulation of Eblasakimab for Future Studies

  1/3/2023

  ASLAN Pharmaceuticals and Thermo Fisher Scientific Inc (NYSE: TMO), the world leader in serving science, today announced a partnership to manufacture a high concentration formulation of eblasakimab for Phase 3 clinical trials.

• ASLAN Pharmaceuticals Announces Participation in January Investor Conferences

  12/16/2022

  ASLAN Pharmaceuticals today announced the Company’s participation in upcoming conferences for January 2023. Listed below are meetings that management will be attending around the week of the J.P. Morgan 41st Annual Healthcare Conference.

• ASLAN Pharmaceuticals Announces First Patient Screened in Study of Eblasakimab in Dupilumab Experienced Atopic Dermatitis Patients

  12/15/2022

  ASLAN Pharmaceuticals today announced that it has screened the first patient in its TREK-DX study of eblasakimab in adult patients with moderate-to-severe atopic dermatitis (AD).

• ASLAN Pharmaceuticals to Participate in a Fireside Chat at 34th Annual Piper Sandler Healthcare Conference

  11/21/2022

  ASLAN Pharmaceuticals today announced Dr Carl Firth, CEO, is scheduled to participate in a fireside chat at the Piper Sandler Healthcare Conference on Thursday, December 1, 2022, at 8:30am ET.

• ASLAN Pharmaceuticals to Participate in Jefferies London Healthcare Conference

  11/8/2022

  ASLAN Pharmaceuticals today announced Dr Carl Firth, CEO, and Mr Stephen Doyle, CBO will be participating in one-on-one meetings at the Jefferies London Healthcare Conference from November 15 to 17, 2022.

• ASLAN Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

  10/28/2022

  ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the third quarter ended September 30, 2022, and provided an update on recent corporate activities.

• ASLAN Pharmaceuticals Commences Clinical Program to Study Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients

  9/14/2022

  ASLAN Pharmaceuticals (“ASLAN”, Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it plans to initiate a new clinical trial of eblasakimab for the treatment of moderate-to-severe atopic dermatitis (AD) in adult patients who have previously been treated with dupilumab.

• ASLAN Pharmaceuticals Announces Acceptance of Two Late-Breaking Abstracts for e-Poster Presentation at the 51st Annual European Society for Dermatological Research Meeting

  9/13/2022

  ASLAN Pharmaceuticals today announced that two abstracts showcasing new translational data on eblasakimab have been accepted as late-breaking e-posters at the 51st Annual European Society for Dermatological Research (ESDR) Meeting, taking place from September 28 to October 1, 2022.

• ASLAN Pharmaceuticals Presents New Data on Eblasakimab in Multiple Posters at the 31st Annual European Academy of Dermatology and Venereology (EADV) Congress

  9/7/2022

  ASLAN Pharmaceuticals announced the presentation of new eblasakimab data at the 2022 European Academy of Dermatology and Venereology annual congress in Milan, Italy.

• ASLAN Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference

  9/2/2022

  ASLAN Pharmaceuticals (Nasdaq:ASLN), today announced Dr Carl Firth, CEO, is scheduled to give an in-person company presentation at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12, 2022, at 10:30 am ET.

• ASLAN Pharmaceuticals Signs License Agreement With Belle.ai to Use belleStudy™ Image Capture Software in Atopic Dermatitis Clinical Trials

  8/25/2022

  BelleTorus Corporation (“Belle.ai”) and ASLAN Pharmaceuticals (Nasdaq: ASLN), today announced that ASLAN has licensed belleStudy™ digital image capture software in support of ASLAN’s clinical trials for atopic dermatitis (AD) across several global sites.

• ASLAN Pharmaceuticals to Host a Hybrid R&D Day on September 15, 2022

  8/22/2022

  Management team will host R&D day on Thursday, September 15, from 10am ET in New York City with Key Opinion Leader (KOL) participation.

• ASLAN Pharmaceuticals Announces Three Abstracts Highlighting New Eblasakimab Data Have Been Accepted as E-Posters at the 31st European Academy of Dermatology and Venereology (EADV) Congress

  8/11/2022

  ASLAN Pharmaceuticals today announced that three abstracts, showcasing new findings related to eblasakimab, will be displayed as e-posters throughout the 31st European Academy of Dermatology and Venereology (EADV) Congress, to be held in-person and virtually from September 7 to 10, 2022.